KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Accured Expenses (2016 - 2025)

Emergent BioSolutions' Change in Accured Expenses history spans 16 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 156.31% year-over-year to $11.6 million; the TTM value through Dec 2025 reached -$10.2 million, down 182.93%, while the annual FY2025 figure was -$10.2 million, 182.93% down from the prior year.
  • Change in Accured Expenses reached $11.6 million in Q4 2025 per EBS's latest filing, up from $6.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $39.9 million in Q3 2024 to a low of -$61.0 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is -$4.2 million, with a median of $5.2 million recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: crashed 703.96% in 2022, then surged 324.16% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $10.1 million in 2021, then plummeted by 703.96% to -$61.0 million in 2022, then surged by 132.46% to $19.8 million in 2023, then tumbled by 204.04% to -$20.6 million in 2024, then surged by 156.31% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Change in Accured Expenses are $11.6 million (Q4 2025), $6.5 million (Q3 2025), and $3.9 million (Q2 2025).